---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Incidence"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Incidence. Topics: U.S. estimated new cases and deaths, 2026; U.S. incidence rate of female breast cancer per 100,000; U.S. incidence rate of HR-positive/HER2-negative breast cancer per 100,000; U.S. share of cases that are HR-positive/HER2-negative, SEER 21, 2019 to 2023; 8 further topics. 12 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/incidence"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Incidence

<a id="heading-2.2.1.2.1"></a>

## 2.2.1.2.1 Incidence of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

<a id="topic-2.2.1.2.1-1"></a>

### U.S. estimated new cases and deaths, 2026

> “In the US in 2026, there will be an estimated 321,910 new cases of invasive breast cancer diagnosed in women and 2,670 cases in men, with an additional 60,730 cases of ductal carcinoma in situ (DCIS) diagnosed in women (Table 1).”

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

<a id="topic-2.2.1.2.1-2"></a>

### U.S. incidence rate of female breast cancer per 100,000

> “The rate of new cases of female breast cancer was 132.5 per 100,000 women per year.”
> “Approximately 13.0 percent of women will be diagnosed with female breast cancer at some point during their lifetime, based on 2021–2023 data.”

Source: [SEER Cancer Stat Facts Female Breast Cancer (2026)](https://seer.cancer.gov/statfacts/html/breast.html)

<a id="topic-2.2.1.2.1-3"></a>

### U.S. incidence rate of HR-positive/HER2-negative breast cancer per 100,000

> “The breast cancer subtype HR+/HER2- is the most common subtype with an age-adjusted rate of 92.9 new cases per 100,000 women, based on 2019–2023 cases.”

Source: [SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026)](https://seer.cancer.gov/statfacts/html/breast-subtypes.html)

<a id="topic-2.2.1.2.1-4"></a>

### U.S. share of cases that are HR-positive/HER2-negative, SEER 21, 2019 to 2023

| Subtype | Percent of cases |
| --- | --- |
| HR+/HER2- | “70%” |
| HR-/HER2- | “11%” |
| HR+/HER2+ | “9%” |
| HR-/HER2+ | “4%” |
| Unknown | “6%” |

Source: [SEER Cancer Stat Facts Female Breast Cancer Subtypes (2026)](https://seer.cancer.gov/statfacts/html/breast-subtypes.html)

<a id="topic-2.2.1.2.1-5"></a>

### U.S. share of cases that are HR-positive/HER2-negative, by race and ethnicity

> “HR+/HER2- breast cancer is the most common subtype in every racial and ethnic group, with the highest proportion (73%) among White women and lowest in Black women (59%).”

Source: [American Cancer Society Breast Cancer Facts and Figures (2024)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/2024/breast-cancer-facts-and-figures-2024.pdf)

<a id="topic-2.2.1.2.1-6"></a>

### U.S. stage distribution at diagnosis, SEER 21

| Stage at diagnosis | Percent of cases |
| --- | --- |
| Localized | “64%” |
| Regional | “27%” |
| Distant | “6%” |
| Unknown | “2%” |

Source: [SEER Cancer Stat Facts Female Breast Cancer (2026)](https://seer.cancer.gov/statfacts/html/breast.html)

<a id="topic-2.2.1.2.1-7"></a>

### U.S. incidence trends, all stages and distant stage

> “The incidence of invasive female breast cancer has been increasing since the mid-2000s; from 2013 to 2022, the rate increased by 1% per year on average, with a steeper pace in women younger than 50 years (1.4% per year)”

Source: [American Cancer Society Cancer Facts and Figures (2026)](https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2026/2026-cancer-facts-and-figures.pdf)

> “Although distant-stage disease rates also increased by 1.1% per year, this likely reflects improved staging because the rate of unstaged disease decreased by a similar magnitude (1.4% per year).”

Source: [Giaquinto et al. (2024)](https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21863)

<a id="topic-2.2.1.2.1-8"></a>

### U.S. annual new metastatic diagnoses, de novo and recurrent

> “The backcalculation method also estimates 50,344 new diagnoses of MBC in 2013, of which 12,966 (26%) are de novo and 37,378 (74%) recurrences, thus 3 in 4 are undocumented diagnoses of MBC.”

Source: [Mariotto et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5833304/)

<a id="topic-2.2.1.2.1-9"></a>

### U.S. new metastatic female breast cancer cases, 2018 estimate and 2025 projection

| Measure | Breast (female) |
| --- | --- |
| Number of new metastatic cancer cases, de novo (observed), 2018 | “15 800” |
| Number of new metastatic cancer cases, de novo and recurrence (estimated), 2018 | “46 666” |
| Projected number of new metastatic (de novo and recurrence) cancer cases, 2025 | “52 126” |

Source: [Gallicchio et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9949565/)

<a id="topic-2.2.1.2.1-10"></a>

### Risk of distant recurrence after 5 years of adjuvant endocrine therapy for ER-positive disease

> “Breast-cancer recurrences occurred at a steady rate throughout the study period from 5 to 20 years.”
> “Among the patients with stage T1 disease, the risk of distant recurrence was 13% with no nodal involvement (T1N0), 20% with one to three nodes involved (T1N1–3), and 34% with four to nine nodes involved (T1N4–9); among those with stage T2 disease, the risks were 19% with T2N0, 26% with T2N1–3, and 41% with T2N4–9.”

Source: [Pan et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5734609/)

<a id="topic-2.2.1.2.1-11"></a>

### Worldwide incidence, GLOBOCAN 2024

> “With an estimated 2.4 million new cases and 694,000 deaths, female breast cancer is the second most commonly diagnosed cancer and the fourth leading cause of cancer death in 2024, accounting for 11.8% of all cases and 7.1% of all deaths”
> “Incidence rates are elevated in Australia/New Zealand, Northern America, and Northern Europe (90–102 per 100,000) and are approximately three times higher than those in Eastern Africa, South Central Asia, and Middle Africa (29–33 per 100,000;”

Source: [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)

<a id="topic-2.2.1.2.1-12"></a>

### Worldwide incidence by human development index

> “Incidence rates are 60% greater in higher versus lower HDI countries (54.1 vs. 33.6 per 100,000), whereas mortality rates are 26% greater in lower HDI countries (14.7 vs. 11.7 per 100,000;”

Source: [Sung et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13343830/)

Additional sources: [Daily et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33750642/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
